Join the Portal
Contact Us
CTSA Pharmaceutical Assets Portal
The ultimate goal of the Portal is to improve collaboration between industry and academia in the area of drug repositioning.
We, the undersigned, call on the pharmaceutical industry to establish a Consortium of pharmaceutical companies with the goal of depositing compounds discontinued at clinical stages to a central repository. The Consortium will make these compounds available for repurposing or screening for new indications to the academic scientists. In particular, the compounds that are no longer under IP protection, and therefore, no longer of strategic interest to the industry may find new applications in the hands of worldwide academic community. Integration of academic investigators into collaborative repositioning efforts will substantially increase the knowledge base and the pool of methodologies available for proof-of-concept studies. This will undoubtedly result in an increased number of approved drugs for new indications and considerable public benefit. The participating industry partners will define the structure of the Consortium, confidential release of information, reasonable mechanisms of compound access, data sharing provisions, and equitable IP benefits.
To read the full text of the Letter please follow this link
The signatories should have an authority to e-sign on behalf of the organization. For password, please contact Peter Ruminski, Center for World Health and Medicine or Kate Marusina, UC Davis CTSC.
Recent News
The CTSA Pharmaceutical Assets Portal and Partnership for Cures jointly support repurposing of the existing drugs
The Portal enters in collaboration with the Partnership for Cures (www.4cures.org), a non-profit organization dedicated to funding Rediscovery Research™ solutions. These solutions include repurposing of existing drugs, testing clinical observations, and modifying treatment protocols. Rediscovery Research Projects will ordinarily make an impact on patients in 1-3 years in the range of $25,000-$250,000 per year. To apply for Rediscovery Research funding, your research organization will need to become a Charter Partner of the Partnership for Cures.
How to become a Charter: (PDF)
To Apply for Research Funding for drug repositioning via Partnership 4 Cures:
http://4cures.doodlekit.com/home/funding_opportunities
The Pharma Portal project is presented at the CHI Conference, Encouraging Development of Therapeutics for Neglected Diseases June 2010
Download the presentation
May 2010. Breaking News: The AP (5/18) reports, "Pfizer Inc. said Monday it will give Washington University $22.5 million and partner with its scientists to discover new uses for existing drug compounds." Pfizer also said it will provide the university "with information on more than 500 drugs and drug candidates," and it "has developed an online portal for university investigators to" review the company's data. Read the full article
Pharmascience is soliciting grant proposals for drug repositioning of brand or generic products and modified formulations, reformulation or new format of delivery.
Deadline is June 28, 2010
More information
The Portal in Nature Medicine, January 2010: Matchmaking service links up researchers to wallflower drugs
January 2010. European Molecular Biology Laboratory's European Bioinformatics Institute launches ChEMBL is a database of 500,000 bioactive compounds, their quantitative properties and bioactivities (binding constants, pharmacology and ADMET, etc). The data is abstracted and curated from the primary scientific literature and the data made available due to funding by the Wellcome Trust. You can search available compounds based on the target and view the detailed ChEBI Compound ID.
http://www.ebi.ac.uk/chembldb/index.php/target
CTSA Pharmaceutical Assest Portal is highlited on the NIH Forecast Report to the Office of the Secretary of Health and Human Services
The
National Center for Research Resources along with the National Cancer
Institute and the Clinical Center at the National Institutes of Health
present:
CTSA Pharmaceutical Assets Portal: Matching Academia and Industry for Drug Repositioning
Friday, December 4, 2009
9:00 a.m. – noon
Lipsett Amphitheater, Building 10, NIH Campus, Bethesda, MD
View Agenda
CTSA Presents the Portal Project at the annual Drug Repositioning Summit in Boston, October 14, 2009
download PDF of the presentation
CTSA Pharma Portal in Proto Magazine, July 2009
Read about the Portal Project in the CTSA Newsletter, March 2,
2009
Membership in the Portal is free for CTSA researchers.
If you have any questions, please contact: Kate Marusina, Ph.D., MBA |
The Portal is sponsored by Clinical and Translational Sciences Award from NCRR,and by Pfizer, and supported by the efforts of: University of California in Davis |